BackgroundRenal cell carcinoma (RCC) is associated with poor prognostic outcomes. The current stratifying system does not predict prognostic outcomes and therapeutic benefits precisely for RCC patients. Here, we aim to construct an immune prognostic predictive model to assist clinician to predict RCC prognosis.MethodsHerein, an immune prognostic signature was developed, and its predictive ability was confirmed in the kidney renal clear cell carcinoma (KIRC) cohorts based on The Cancer Genome Atlas (TCGA) dataset. Several immunogenomic analyses were conducted to investigate the correlations between immune risk scores and immune cell infiltrations, immune checkpoints, cancer genotypes, tumor mutational burden, and responses to chemotherapy an...
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. Currently, we la...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Immune status affects the initiation and progression of clear cell renal cell carcinoma (ccRCC), the...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Background. Immunity exerts momentous functions in the progression and treatment of kidney renal cle...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Clear Cell Renal Carcinoma (ccRCC) accounts for nearly 80% of renal carcinoma cases, and immunothera...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Abstract Background Considerable evidence has indicated an association between the immune microenvir...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Purpose. To construct a survival model for predicting the prognosis of patients with kidney renal cl...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. Currently, we la...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Immune status affects the initiation and progression of clear cell renal cell carcinoma (ccRCC), the...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Background. Immunity exerts momentous functions in the progression and treatment of kidney renal cle...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Clear Cell Renal Carcinoma (ccRCC) accounts for nearly 80% of renal carcinoma cases, and immunothera...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Abstract Background Considerable evidence has indicated an association between the immune microenvir...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Purpose. To construct a survival model for predicting the prognosis of patients with kidney renal cl...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. Currently, we la...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...
Background: Currently, there are no useful biomarkers or prognostic risk markers for the diagnosis o...